Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the screening defined as:~  * aCL IgG/M (\>40U,medium-to-high titer,and/or greater than the 99th percentile)and/or~ * aβ2GPI IgG/M(\>40U, medium-to-high titer, and/or greater than the 99th percentile)and/or~ * Positive LA test based on the International Society of Thrombosis \& Haematosis Recommendations~Selected Exclusion Criteria:~* History of thrombosis (arterial, venous, and/or biopsy proven microthrombosis~* History of Transient Ischemic Attack Confirmed by a Neurologist~* SLE Diagnosis based on the ACR Classification Criteria \> 4/11~* Other Systemic Autoimmune Diseases diagnosed based on ACR Classification Criteria~* Current Hydroxychloroquine or another antimalarial treatment (-3 months)~* Current warfarin treatment (-3 months)~* Current heparin therapy( -3 months)~* Current pregnancy~* History of Hydroxychloroquine eye toxicity~* History of Hydroxychloroquine allergy~* Known glucose-6-phosphate dehydrogenase deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Standard treatment (Type: NO_INTERVENTION): patients randomized to standard treatment will not receive hydroxychloroquine.
- Hydroxychloroquine (Type: EXPERIMENTAL): Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing \<60kg; and 400 mg daily (200 mg twice a day)for patients weighing \>60kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).